JP2017506214A - 癌を治療するためのFrizzled受容体抗体 - Google Patents

癌を治療するためのFrizzled受容体抗体 Download PDF

Info

Publication number
JP2017506214A
JP2017506214A JP2016544451A JP2016544451A JP2017506214A JP 2017506214 A JP2017506214 A JP 2017506214A JP 2016544451 A JP2016544451 A JP 2016544451A JP 2016544451 A JP2016544451 A JP 2016544451A JP 2017506214 A JP2017506214 A JP 2017506214A
Authority
JP
Japan
Prior art keywords
antibody
tumor
antigen
seq
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016544451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506214A5 (cg-RX-API-DMAC7.html
Inventor
デケル、ベンジャミン
ポデ−シェイキッド、ナオミ
ハラリ−スタインバーグ、オリト
マーク−ダニエル、ミカル
バックス、エイナブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2017506214A publication Critical patent/JP2017506214A/ja
Publication of JP2017506214A5 publication Critical patent/JP2017506214A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016544451A 2014-01-02 2015-01-01 癌を治療するためのFrizzled受容体抗体 Pending JP2017506214A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461922893P 2014-01-02 2014-01-02
US61/922,893 2014-01-02
PCT/IL2015/050009 WO2015101998A1 (en) 2014-01-02 2015-01-01 Frizzled receptor antibodies for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2017506214A true JP2017506214A (ja) 2017-03-02
JP2017506214A5 JP2017506214A5 (cg-RX-API-DMAC7.html) 2018-01-25

Family

ID=53493369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544451A Pending JP2017506214A (ja) 2014-01-02 2015-01-01 癌を治療するためのFrizzled受容体抗体

Country Status (6)

Country Link
US (1) US10465004B2 (cg-RX-API-DMAC7.html)
EP (1) EP3089995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017506214A (cg-RX-API-DMAC7.html)
CA (1) CA2935630A1 (cg-RX-API-DMAC7.html)
IL (1) IL246540A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015101998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer
WO2017100154A1 (en) * 2015-12-07 2017-06-15 Purdue Research Foundation Inhibitors for proliferating cell nuclear antigen and uses
CN112159474B (zh) * 2019-11-06 2021-11-19 上海健康医学院 一种靶向Frizzled7人源化抗体及其制备方法与应用
WO2026051924A1 (zh) * 2024-09-03 2026-03-12 浙江道尔生物科技有限公司 抗fzd7单域抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036179A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
US20100104574A1 (en) * 2008-09-26 2010-04-29 Gurney Austin L Frizzled-Binding Agents and Uses Thereof
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500360B1 (en) * 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036179A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
US20100104574A1 (en) * 2008-09-26 2010-04-29 Gurney Austin L Frizzled-Binding Agents and Uses Thereof
JP2012503990A (ja) * 2008-09-26 2012-02-16 オンコメッド ファーマシューティカルズ インコーポレイテッド frizzled結合剤およびその使用
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATA SHEET:: FZD7 ANTIBODY-C-TERMINAL REGION (ARP41251_P050)− AVIVA SYSTEMS BIOLOGY, JPN6018042500, ISSN: 0004205501 *
KING T.D. ET AL., CELL SIGNAL, vol. Vol.24, No.4(2012), JPN6018042501, pages 846 - 851, ISSN: 0004205502 *
UENO K. ET AL., NEOPLASIA, vol. Vol.10, No.7(2008), JPN6018042499, pages 697 - 705, ISSN: 0004205500 *

Also Published As

Publication number Publication date
WO2015101998A1 (en) 2015-07-09
EP3089995A1 (en) 2016-11-09
CA2935630A1 (en) 2015-07-09
US20160326245A1 (en) 2016-11-10
IL246540A0 (en) 2016-08-31
EP3089995A4 (en) 2017-11-29
US10465004B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
DK2481756T3 (en) Compositions and Methods for Diagnosing and Treating Cancer
JP2009513708A6 (ja) 癌の診断および処置のための組成物および方法
HK1208687A1 (en) Rspo3 binding agents and uses thereof
US20170266276A1 (en) Combination Therapy For Treatment of Cancer
JP2015536933A (ja) Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
US20170247465A1 (en) Combination therapy for treatment of cancer
JP2015502958A (ja) がんの処置のための併用療法
CN102812044A (zh) Wnt结合剂及其用途
US20140186342A1 (en) Compositions and Methods for Diagnosing and Treating Cancer
US10465004B2 (en) Frizzled receptor antibodies for treatment of cancer
US20170247437A1 (en) Rspo1 binding agents and uses thereof
CN101356679A (zh) 用于诊断和治疗癌症的组合物和方法
HK1178915A (en) Wnt-binding agents and uses thereof
HK1179275B (en) Compositions and methods for diagnosing and treating cancer
HK1199209B (en) Vegf/dll4 binding agents and uses thereof
HK1174047A (en) Compositions and methods for diagnosing and treating cancer
HK1199209A1 (en) Vegf/dll4 binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204